Canada's Most Trusted Source Discreet 2–5 Day Domestic Shipping FREE SHIPPING ON ORDERS OVER $500

Semaglutide, tirzepatide and retatrutide all work by copying gut hormones, starting with GLP-1. Cagrilintide copies something else entirely. It is built on amylin, a hormone your pancreas releases at the same moment it releases insulin.

On its own it is a decent weight loss compound. Paired with semaglutide it produced some of the biggest numbers any obesity trial has reported.

What amylin does

When you eat, the beta cells in your pancreas release insulin and amylin together. Insulin deals with the sugar. Amylin deals with the meal.

It slows how fast your stomach empties, so food stays with you longer. It signals fullness to the brainstem. And it holds back glucagon after a meal, which stops your liver dumping extra sugar into your blood while you are already digesting.

Natural amylin breaks down in minutes. A version of it called pramlintide has been used for years as a mealtime injection for diabetes, but it has to be taken before every meal.

What cagrilintide is

Cagrilintide is a long acting amylin analogue developed by Novo Nordisk, the company behind semaglutide. The changes to its structure let it last long enough to inject once a week rather than before every meal.

That once weekly schedule is what makes it practical to combine with semaglutide, which runs on the same weekly rhythm. The combination is called CagriSema.

What the phase 3 trial found

The main trial is REDEFINE 1, published in the New England Journal of Medicine in June 2025. It enrolled 3,417 adults with obesity, or overweight plus a weight related health problem, and without type 2 diabetes. It ran for 68 weeks.

People were split into four groups. The numbers below are for people who stayed on treatment:

GroupWeight lost at 68 weeks
CagriSema (both together)22.7%
Semaglutide 2.4mg alone16.1%
Cagrilintide 2.4mg alone11.8%
Placebo2.3%

Counting everyone, including people who stopped or missed doses, CagriSema came out at 20.4 percent against 3.0 percent for placebo.

Among people who stuck with it, 40.4 percent lost at least a quarter of their body weight and 23.1 percent lost at least 30 percent. About half of the participants who started with obesity finished below the obesity threshold, from an average starting BMI of 38.

A second trial, REDEFINE 2, ran the same 68 weeks in 1,206 people who did have type 2 diabetes. Weight loss there was 15.7 percent against 3.1 percent for placebo. People with diabetes lose less on every compound in this class, so that gap is expected.

Fat versus lean mass

This is the question that comes up with every weight loss compound now, and REDEFINE 1 measured it in a subgroup of 252 people.

Fat mass dropped by 35.7 percent. Lean soft tissue dropped by 14.4 percent. On placebo those figures were 5.7 and 4.3 percent.

So most of what came off was fat, but not all of it. Losing lean tissue during heavy weight loss happens with every compound in this category and with diet alone too. Our piece on GLP-1s and bone density goes into the related concern about what else gets lost.

Side effects

Mostly gastrointestinal, which is the pattern for the whole class.

In REDEFINE 1, 79.6 percent of people on CagriSema reported a stomach or gut side effect, against 39.9 percent on placebo. Nausea hit 55 percent, against 12.6 percent. Constipation was 30.7 percent, vomiting 26.1 percent.

Most of it was described as mild to moderate and temporary. 5.9 percent stopped because of side effects, against 3.7 percent on placebo.

Amylin slowing the stomach on top of semaglutide slowing the stomach is the obvious reason nausea runs high. Two compounds pushing the same direction.

Where it stands now

CagriSema is still investigational. Novo Nordisk submitted it to the US FDA in December 2025, and a decision is expected during 2026. It is not approved for sale in Canada.

The trial program is not finished either. REDEFINE 3 is tracking heart outcomes. REDEFINE 4 is an 84 week head to head against tirzepatide, which is the comparison everyone actually wants to see.

How it fits next to what already exists

Cagrilintide on its own, at 11.8 percent, sits below semaglutide. That is not its point. Its point is that amylin and GLP-1 work through different signals, so stacking them adds rather than overlaps.

That is the same logic behind tirzepatide adding GIP to GLP-1, and retatrutide adding glucagon on top of both. Our comparison of semaglutide and tirzepatide and the retatrutide guide cover those two routes. If the underlying mechanism is new to you, start with how GLP-1s work.

Questions

Is cagrilintide a GLP-1?
No. It is an amylin analogue. It works on a completely separate hormone system, which is why combining it with a GLP-1 adds to the effect.

Is CagriSema stronger than tirzepatide?
That is exactly what REDEFINE 4 is testing. Until it reports, any answer is a guess based on comparing different trials.

How is it taken?
In the trials, as a once weekly injection under the skin. We do not provide dosing protocols.

Does weight come back after stopping?
For semaglutide and tirzepatide, a good portion of lost weight tends to return after stopping. There is no reason yet to expect CagriSema to behave differently, but the long term data is not out.

Why is nausea so common?
Both halves of CagriSema slow down the stomach. Doubling up on that effect doubles up on the side effect.

Is it approved anywhere?
Not as of the latest information. The FDA review is underway.

The short version

Cagrilintide is the first long acting version of a hormone the body already uses to tell you a meal is enough. Alone it is modest. Paired with semaglutide it produced a 22.7 percent average loss in people who stayed on it, with a lot of nausea along the way.

Semaglutide, the other half of that pairing, is in the peptide range along with the rest of what we carry.

Sold for research purposes only. Cagrilintide and CagriSema are not approved by Health Canada, and we do not provide dosing protocols. Nothing here is medical advice.

[]